ChromaDex (NASDAQ:CDXC) announces encouraging results from a pilot study evaluating nicotinamide riboside (NR), or Niagen, in patients with Stage D (advanced) heart failure.
Results from the NIH-funded study showed that Niagen supplementation reduced signs of inflammation in a small group of end-stage heart failure patients.
A second arm of the study, conducted on peripheral blood cells, found improved mitochondrial respiration and reduced inflammatory factor expression.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.